Related Experiment Video
Updated: Apr 4, 2026
05:59
Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
Published on: October 20, 2023
3.3K
Current, emerging, and newly available insomnia medications
1From the Insomnia and Sleep Research Program, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina.
The Journal of Clinical Psychiatry
|September 4, 2015
Summary
New insomnia medications target wake-promoting systems, offering improved efficacy and fewer side effects compared to current GABA-targeting drugs. This research advances sleep-wake cycle understanding for better insomnia treatment.
Area of Science:
- Neuroscience
- Pharmacology
- Sleep Medicine
Background:
- Current insomnia treatments broadly target GABA systems, leading to side effects and limited efficacy.
- Existing sleep aids include antidepressants, antipsychotics, and antihistamines, but their use is restricted by adverse effects.
Purpose of the Study:
- To explore novel therapeutic targets within the sleep-wake cycle for insomnia.
- To evaluate emerging insomnia medications with selective antagonism mechanisms.
Main Methods:
- Review of current and emerging insomnia pharmacotherapies.
- Analysis of drug mechanisms targeting sleep-wake regulatory systems.
Main Results:
- GABA-targeting drugs (benzodiazepines, nonbenzodiazepines) enhance sleep promotion broadly.
- Newer agents selectively antagonize orexin, serotonin, and norepinephrine to block wakefulness.
- Selective antagonism shows potential for improved efficacy and reduced adverse effects.
Conclusions:
- Emerging insomnia medications targeting wake-promoting systems offer a promising alternative.
- Selective antagonism represents a significant advancement in sleep medicine and insomnia treatment.
Related Concept Videos
01:19Management of Insomnia
782
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
782
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
865
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
865
01:23Sedatives and Hypnotics: Overview
2.1K
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
2.1K
01:27Insomnia
591
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
591
01:14CNS Depressants: Barbiturates and Benzodiazepines
1.7K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.7K
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
1.3K
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
1.3K